Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.39 |
| ▸ | AGER | Q15109 | 7/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729281 | 0.92 | AGER (0.46) | TRPV4AGER | |
| SCHEMBL727314 | 0.91 | TRPV4 (0.46) | TRPV4HRH3KCNH2 | |
| SCHEMBL729132 | 0.90 | AGER (0.39) | TRPV4AGERESR1HDAC1HDAC6 | |
| SCHEMBL727888 | 0.88 | AGER (0.40) | TRPV4AGERESR1HDAC1HDAC6 | |
| SCHEMBL729448 | 0.88 | AGER (0.40) | TRPV4AGERESR1HDAC1HDAC6 | |
| SCHEMBL727562 | 0.87 | AGER (0.38) | TRPV4AGERESR1HDAC1HDAC6 | |
| SCHEMBL729341 | 0.85 | TRPV4 (0.43) | TRPV4HRH3KCNH2 | |
| SCHEMBL729054 | 0.85 | AGER (0.49) | AGER | |
| SCHEMBL727809 | 0.85 | AGER (0.42) | AGERHRH3KCNH2 | |
| SCHEMBL727516 | 0.83 | ATP4A (0.41) | AGERHRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011529876-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-8008329-B2 | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-08-30 | — | — | US | claimed |
| EP-1979334-B1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARM CO LTD (KR) | 2011-06-22 | — | — | EP | claimed |
| US-7943646-B2 | Benzamidine derivative, process for the preparation thereof and pharmaceutical composition comprising same | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-05-17 | — | — | US | claimed |
| EP-2307016-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | Dong Wha Pharmaceutical Co., Ltd. (KR) | 2011-04-13 | — | — | EP | claimed |
| WO-2010013975-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2010-02-04 | — | — | WO | claimed |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | Dong Wha Pharm, Co. Ltd. (KR) | 2010-02-04 | — | — | US | claimed |
| US-20090054642-A1 | NOVEL BENZAMIDINE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DONGWHA PHARMACEUTICAL IND. CO., LTD. (KR) | 2009-02-26 | — | — | US | claimed |
| US-8008329-B2 | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-08-30 | — | — | US | disclosed |
| EP-1979334-B1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARM CO LTD (KR) | 2011-06-22 | — | — | EP | disclosed |
| US-7943646-B2 | Benzamidine derivative, process for the preparation thereof and pharmaceutical composition comprising same | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2011-05-17 | — | — | US | disclosed |
| EP-2307016-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | Dong Wha Pharmaceutical Co., Ltd. (KR) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010013975-A2 | A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVE OR ITS SALT, AND BISPHOSPHONATE | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | Dong Wha Pharm, Co. Ltd. (KR) | 2010-02-04 | — | — | US | disclosed |
| US-20090054642-A1 | NOVEL BENZAMIDINE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DONGWHA PHARMACEUTICAL IND. CO., LTD. (KR) | 2009-02-26 | — | — | US | disclosed |
| EP-1979334-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dong Wha Pharmaceutical. Ind. Co., Ltd. (KR) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089101-A1 | NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARMACEUTICAL IND.CO., LTD. (KR) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054642-A1 | NOVEL BENZAMIDINE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SOST, BMP4, BST2 | TRPV4 350/4885AGER 626/4885ESR1 4087/4885 |
| US-20100029596-A1 | METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE | SOST, BPGM, PTH1R | TRPV4 822/4885AGER 489/4885ESR1 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.